Scientific research

The Science

Reversing Age-Related Immune Decline

The first clinical trials to demonstrate thymus regeneration and epigenetic age reversal in humans.

Explore the Research
2.5 yrs
Epigenetic age reversal
+63%
New T cells from thymus
+21%
VO2max improvement
~16 yr
T cell production half-life

The Thymus: Key to Immune Regeneration

The thymus gland produces T cells—your immune system's primary defense against infections and cancer. Starting around puberty, the thymus begins to shrink and is gradually replaced by fat tissue.

Research published in PNAS demonstrates that this thymic decline—not just mutation accumulation—is the primary driver of age-related cancer risk. T cell production declines with a half-life of approximately 16 years, leaving the immune system progressively unable to eliminate cancerous cells.

Our research demonstrates that this decline can be reversed through carefully designed intervention protocols, restoring immune function and reversing biological age as measured by epigenetic clocks.

Thymus and Reducing Cancer Risk
Thymus aging diagram

The thymus shrinks dramatically with age, replaced by fat tissue

T cell repertoire decline with age

T cell repertoire collapses dramatically after age 65

The Problem

Thymic Involution Causes Immunosenescence

The thymus is the master regulator of your immune system. Starting around puberty, it begins to shrink and is gradually replaced by fat tissue. By age 65-75, this leads to a massive collapse in immune competence.

The naive T cell repertoire declines dramatically while memory cells accumulate, leaving the immune system unable to respond effectively to new threats.

80%
Thymic function loss by 65
3x
Mortality risk without thymus
NEJM 2023

Landmark Research

The TRIIM Trial

The first human clinical study to demonstrate successful thymus regeneration and reversal of epigenetic aging.

"This has huge implications not just for infectious disease but also for cancer and ageing in general."

— Dr. Sam Palmer, in Nature

Thymic Regeneration Confirmed

MRI evidence of improved thymic structure and function

Epigenetic Age Reversal

2.5 years average reversal across all established clocks

Favorable Safety Profile

Mild side effects were dose-dependent and reversible

2.5
Years Reversed
Epigenetic age
9
Participants
Completed trial
51-65
Age Range
Years old
12
Months
Treatment period

Extended Research

The TRIIM-X Trial

Building on the original study with a larger cohort, broader demographics, and longer follow-up.

85
Participants
Enrolled in trial
40-80
Age Range
Broader demographic
+63%
Thymic Emigrants
New T cells
+21%
VO2max
Physical fitness improvement

Age Reversal Validated

Epigenetic benefits mirrored those seen in the original TRIIM trial

Improved Physical Fitness

Significant gains in VO2max and functional capacity

Women Included

Extended study to include female participants

Join the Future of Immune Regeneration

Learn how you can participate in our programs or access personalized treatment protocols.